Marcin Zakrzewski

Mr. Marcin Zakrzewski

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
PBPatrycja Bełdzińska
Patrycja Bełdzińska
BGBarbara Galikowska-Bogut
Barbara Galikowska-Bogut
MZMarcin Zakrzewski
Marcin Zakrzewski
KBKatarzyna Bury
Katarzyna Bury
MJMarzena Jamrógiewicz
Marzena Jamrógiewicz
Jacek PiosikJacek Piosik
Jacek Piosik

5 April 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PBPatrycja Bełdzińska
Patrycja Bełdzińska
MZMarcin Zakrzewski
Marcin Zakrzewski
IMInez Mruk
Inez Mruk
MBMarceli Bogusławski
Marceli Bogusławski
NDNatalia Derewońko
Natalia Derewońko
Jacek PiosikJacek Piosik
Jacek Piosik
Cancer is a leading cause of death worldwide, with nearly 10 million fatalities yearly. Consequently, despite the search for new therapeutic approaches, the use of classical chemotherapy, remains one of the main treatment regimens. Therefore, we evaluate the use of platinum nanoparticles (PtNPs) of different sizes as potential modulators of doxorubicin (DOX) activity. In the presented research, we utilized a wide range of methods, including Spectroscopic measurements, Isothermal Titration Calorimetry, Dynamic Light Scattering, and Atomic Force Microscopy, as well as biological assays such as the Ames mutagenicity test on Salmonella enterica serovar Typhimurium TA98 and the alamarBlue cytotoxicity assay with Fluorescent Confocal Microscopy on non-cancerous HaCaT and cancerous MelJuSo cell lines, to investigate the interactions between PtNPs and DOX and the effect of diverse-sized nanoparticles on DOX activity. The obtained results indicate the presence of direct interactions, particularly highlighting differences related to particles size. We confirmed that DOX affects the aggregation of nanoparticles, while the nanoparticles induce DOX fluorescence quenching. In terms of biological aspects, PtNPs reduced the mutagenicity of DOX, and increased the survival of non-cancerous HaCaT cells. Furthermore, 70 nm PtNPs significantly increased DOX effects on cancerous MelJuSo cells by negatively affecting their morphology and culture density. To conclude, our research provided valuable insights into the interactions between PtNPs and DOX with particular emphasis on the nanoparticles' size influence highlighting nanoparticles' impact on DOX cytotoxicity providing a base for further research on the potential future modification in treatment approaches.

10 September 2025 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
PBPatrycja Bełdzińska
Patrycja Bełdzińska
MZMarcin Zakrzewski
Marcin Zakrzewski
KGKatarzyna Grzyb
Katarzyna Grzyb
AHAmandine Hauer
Amandine Hauer
MJMarzena Jamrógiewicz
Marzena Jamrógiewicz
Jacek PiosikJacek Piosik
Jacek Piosik
In 2022, nearly 20 million new cancer cases were diagnosed worldwide. Despite undeniable improvement in cancer treatment, chemotherapy, a frequently used method, remains limited due to severe side effects. Hence, in this research we utilized platinum nanoparticles (PtNPs) of varying sizes to investigate their interactions with epirubicin (EPI), a commonly used anticancer drug, and asses their impact on its biological activity. We employed various physicochemical methods, including Fluorescence and Infrared Spectroscopies, Differential Scanning Calorimetry, Isothermal Titration Calorimetry, Atomic Force Microscopy and Dynamic Light Scattering with Zeta Potential measurements, to investigate the interactions and aggregation patterns of PtNPs with EPI. Moreover, the biological effect of these interactions, with a particular emphasis on the differences due to nanoparticles' sizes, was verified in Ames mutagenicity test on Salmonella enterica serovar Typhimurium TA98 and through cytotoxicity assays on MelJuSo (cancerous) and HaCaT (non-cancerous) cell lines. The obtained results confirmed the presence of PtNPs-EPI interactions depending on the nanoparticles' size. The physicochemical analyses revealed the formation of EPI-induced aggregates of nanoparticles, which may be of great importance in the context of the biological effects. Consequently, the biological part indicated that PtNPs decrease EPI mutagenicity and increase its cytotoxicity in cancerous cell line. In the contrary, nanoparticles exhibited a potential protective effect on cells and mostly increased or maintained the cells viability in non-cancerous cell line. Summing up, our research provides valuable insights into the PtNPs influence on epirubicin with special focus on the differences attributed to nanoparticles sizes.

22 September 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
MZMarcin Zakrzewski
Marcin Zakrzewski
PBPatrycja Bełdzińska
Patrycja Bełdzińska
FGFelicja Gajdowska
Felicja Gajdowska
GGGrzegorz Gołuński
Grzegorz Gołuński
KGKarolina Gackowska
Karolina Gackowska
Jacek PiosikJacek Piosik
Jacek Piosik
Cancer is a difficult disease to cure due to its diversity and complexity. Despite novel therapeutic approaches having been proposed in recent years, chemotherapy remains one of the most common treatment regimens to this day. Unfortunately, its anticancer effects are often quelled by the lack of selectivity; hence alteration of the activity of already existing drugs by combining them with potential modulators e.g. metallic nanoparticles has been proposed as a possible strategy to overcome this problem. Herein, we verified if platinum nanoparticles (PtNPs) of various sizes interact with daunorubicin (DAU), a chemotherapeutic agent used for the treatment of leukaemia. Utilizing DLS and NTA we observed nanoparticle aggregation upon addition of increasing concentrations of DAU. Furthermore, we noticed that PtNPs quench DAU's fluorescence, suggesting their direct interaction. Next, we used FTIR and NIR spectroscopies and registered significant changes in the obtained spectra in the presence of PtNPs. The ITC and DSC analyses showed that all tested sizes of PtNPs interact with DAU in an endothermic manner, with the enthalpy change between 0.47 and 4.36 kcal mol−1. The release analysis employing the dialysis bag method evidenced that PtNPs influence DAU's diffusion kinetics, decreasing its release from 100% (when alone) to ca. 70% when combined with PtNPs. All tested sizes of PtNPs reduce DAU's mutagenicity towards S.enterica serovar Typhimurium TA98 strain, however, no significant influence on DAU's cytotoxicity was observed on neither MelJuSo nor HaCaT eukaryotic cell lines. Overall, these results indicate that PtNPs may affect DAU's biological activity and warrant further biological studies.

6 May 2025 in Materials
Verified
Journal Article
Open access
PDF file
Yuriy PrylutskyyYuriy Prylutskyy
Yuriy Prylutskyy
PBPatrycja Bełdzińska
Patrycja Bełdzińska
NDNatalia Derewońko
Natalia Derewońko
THTetiana Halenova
Tetiana Halenova
NRNataliia Raksha
Nataliia Raksha
Jacek PiosikJacek Piosik
Jacek Piosik
Graphene oxide (GO), owing to its extraordinary application prospects in biomedicine, is attracting growing research attention. However, the biosafety and blood compatibility of GO required for its clearance for use in clinical trials remain elusive. Therefore, we studied the mutagenic properties of GO as well as its cell toxicity and blood compatibility. Prior to biological experiments, we assessed the structural organization of GO using dynamic light scattering and microscopic visualization methods. The results of both the Ames mutagenicity test performed on Salmonella enterica serovar Typhimurium TA98 and TA102 strains and the cytotoxicity test on noncancerous, immortalized human keratinocytes revealed no mutagenic or toxic effects of GO. Simultaneously, GO reduced the viability of the MelJuSo human melanoma cell line. A blood compatibility assay revealed that a concentration of 10 μg/mL was critical for GO biosafety, as greater concentrations induced diverse side effects. Specifically, GO disrupts erythrocytes’ membranes in the dose-dependent manner. Moreover, GO at higher concentrations both inhibited the process of ADP (a physiological platelet agonist)-induced cell aggregation and affected their disaggregation process in platelet-rich plasma. However, in the blood clotting assessment, GO showed no effects on the activated partial thromboplastin time, prothrombin time, or thrombin time of the platelet-poor plasma. The obtained results clearly indicate that the relationship between the GO preparation method, its size, and concentration and biosafety must be cautiously monitored in the context of further possible biomedical applications.

11 September 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MZMarcin Zakrzewski
Marcin Zakrzewski
IKIzabela Kalisz
Izabela Kalisz
PBPatrycja Bełdzińska
Patrycja Bełdzińska
KGKatarzyna Grzyb
Katarzyna Grzyb
KBKatarzyna Bury
Katarzyna Bury
JPJacek Piosik
Jacek Piosik